UNITY Biotechnology, Inc. to Participate in Upcoming Investor Conferences
September 07 2021 - 4:00PM
UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology
company developing therapeutics to slow, halt, or reverse diseases
of aging, today announced that members of its senior management
team will participate at the following September virtual investor
conferences:
16th Annual Citi
BioPharma ConferenceDate: September 8, 2021 Format: 1x1
meetings
Morgan Stanley 19th
Annual Global Healthcare ConferenceDate: September
9, 2021 Presentation Time: 10:15 a.m. ET and 1x1 meetings
23rd H.C. Wainwright
Global Investment ConferenceDate: September 13,
2021On-demand Presentation Available: 7:00 a.m. ET and 1x1
meetings
Cantor Virtual Global Healthcare
ConferenceDate: September 29, 2021Presentation
Time: 10:40 a.m. ET and 1x1 meetings
If you are interested in arranging a 1x1 meeting
at any of the events, please contact your bank conference
representative or UNITY at ir@unitybiotechnology.com. For more
details and to access webcasts of the presentations, please see the
Events and Presentations section of UNITY’s corporate website.
About UNITY
UNITY is developing a new class of therapeutics
to slow, halt, or reverse diseases of aging. UNITY’s current focus
is on creating medicines to selectively eliminate or modulate
senescent cells and thereby provide transformative benefit
in age-related ophthalmologic and neurologic diseases.
More information is available
at www.unitybiotechnology.com or follow us
on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking
statements including statements related to UNITY’s understanding of
cellular senescence and the role it plays in diseases of aging, the
potential for UNITY to develop therapeutics to slow, halt, or
reverse diseases of aging, including for ophthalmologic and
neurologic diseases, our expectations regarding potential benefits,
activity, effectiveness, and safety of UBX1325, the potential for
UNITY to successfully commence and complete clinical studies of
UBX1325 for DME, AMD, and other ophthalmologic diseases, the
expected timing of results of our studies of UBX1325, the timing of
the expected commencement, progression, and conclusion of our
studies including those of UBX1325, and UNITY’s expectations
regarding the sufficiency of its cash runway. These statements
involve substantial known and unknown risks, uncertainties, and
other factors that may cause our actual results, levels of
activity, performance, or achievements to be materially different
from the information expressed or implied by these forward-looking
statements, including the risk that
the COVID-19 worldwide pandemic may continue to
negatively impact the development of preclinical and clinical drug
candidates, including delaying or disrupting the enrollment of
patients in clinical trials, risks relating to the uncertainties
inherent in the drug development process, and risks relating to
UNITY’s understanding of senescence biology. We may not actually
achieve the plans, intentions, or expectations disclosed in our
forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Actual results or events could
differ materially from the plans, intentions, and expectations
disclosed in the forward-looking statements we make. The
forward-looking statements in this press release represent our
views as of the date of this release. We anticipate that subsequent
events and developments will cause our views to change. However,
while we may elect to update these forward-looking statements at
some point in the future, we have no current intention of doing so
except to the extent required by applicable law. You should,
therefore, not rely on these forward-looking statements as
representing our views as of any date subsequent to the date of
this release. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of UNITY in general, see UNITY’s most
recent Quarterly Report on Form 10-Q for the quarter
ended June 30, 2021, filed with the Securities and
Exchange Commission on August 10, 2021, as well as other
documents that may be filed by UNITY from time to time with
the Securities and Exchange Commission.
Media
Canale Communications
Jason Spark
jason.spark@canalecomm.com
UNITY Biotechnology (NASDAQ:UBX)
Historical Stock Chart
From Sep 2024 to Oct 2024
UNITY Biotechnology (NASDAQ:UBX)
Historical Stock Chart
From Oct 2023 to Oct 2024